Literature DB >> 11963798

Lp-PLA2: an emerging biomarker of coronary heart disease.

Nisha Dada1, Nam W Kim, Robert L Wolfert.   

Abstract

Cardiovascular disease is the leading cause of death in most industrialized countries. However, the diagnosis and management of coronary heart disease is far from optimal. Lipoprotein-associated phospholipase A2 (Lp-PLA2), also known as platelet-activating factor acetylhydrolase, is an enzyme that hydrolyses oxidized phospholipids and is primarily associated with low-density lipoprotein. Discussed in this review is the accumulating evidence supporting the view that Lp-PLA2 is a potential biomarker of coronary heart disease and plays and an important proinflammatory role in the progression of atherosclerosis. A new ELISA method for the quantitative measurement of Lp-PLA2 mass in human plasma developed by diaDexus, Inc. is presented. Furthermore, potential clinical applications of Lp-PLA2 mass measurements are proposed.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 11963798     DOI： 10.1586/14737159.2.1.17

Source DB:  PubMed          Journal:  Expert Rev Mol Diagn        ISSN： 1473-7159            Impact factor:   5.225


  25 in total

1.  Cloning, expression, and purification of lipoprotein-associated phospholipase A(2) in Pichia pastoris.

Authors:  Fujun Zhang; Yiping Wang
Journal:  Mol Biotechnol       Date:  2006-05       Impact factor: 2.695

Review 2.  Candidate-based proteomics in the search for biomarkers of cardiovascular disease.

Authors:  Leigh Anderson
Journal:  J Physiol       Date:  2004-12-20       Impact factor: 5.182

3.  Age as a modulator of inflammatory cardiovascular risk factors.

Authors:  Erdembileg Anuurad; Byambaa Enkhmaa; Zeynep Gungor; Wei Zhang; Russell P Tracy; Thomas A Pearson; Kyoungmi Kim; Lars Berglund
Journal:  Arterioscler Thromb Vasc Biol       Date:  2011-06-23       Impact factor: 8.311

4.  Interaction between nonsynonymous polymorphisms in PLA2G7 gene and smoking on the risk of coronary heart disease in a Chinese population.

Authors:  Yunpeng Chi; Conghong Shi; Xiaojiang Zhang; Yang Xi
Journal:  J Thromb Thrombolysis       Date:  2018-07       Impact factor: 2.300

5.  Associations of platelet-activating factor acetylhydrolase gene polymorphisms with risk of ischemic stroke.

Authors:  Yongsheng Ma
Journal:  Biomed Rep       Date:  2015-12-21

6.  Nonsynonymous polymorphisms in PLA2G7 gene are associated with the risk of coronary heart disease in a southern Chinese population.

Authors:  Mei Hong; Mengyao Zhang; Xiang Lu
Journal:  Mamm Genome       Date:  2015-02-18       Impact factor: 2.957

7.  Biomarkers and degree of atherosclerosis are independently associated with incident atherosclerotic cardiovascular disease in a primary prevention cohort: The ARIC study.

Authors:  Anandita Agarwala; Salim Virani; David Couper; Lloyd Chambless; Eric Boerwinkle; Brad C Astor; Ron C Hoogeveen; Joe Coresh; A Richey Sharrett; Aaron R Folsom; Tom Mosley; Christie M Ballantyne; Vijay Nambi
Journal:  Atherosclerosis       Date:  2016-08-25       Impact factor: 5.162

8.  Lipoprotein-associated phospholipase A2 and high-sensitivity C-reactive protein improve the stratification of ischemic stroke risk in the Atherosclerosis Risk in Communities (ARIC) study.

Authors:  Vijay Nambi; Ron C Hoogeveen; Lloyd Chambless; Yijuan Hu; Heejung Bang; Josef Coresh; Hanyu Ni; Eric Boerwinkle; Thomas Mosley; Richey Sharrett; Aaron R Folsom; Christie M Ballantyne
Journal:  Stroke       Date:  2008-12-18       Impact factor: 7.914

9.  Prevalence of non-alcoholic fatty liver and characteristics in overweight adolescents in the general population.

Authors:  Armin Imhof; Wolfgang Kratzer; Bernhard Boehm; Katrin Meitinger; Gerlinde Trischler; Gerald Steinbach; Isolde Piechotowski; Wolfgang Koenig
Journal:  Eur J Epidemiol       Date:  2007-09-25       Impact factor: 8.082

10.  Lipoprotein-associated phospholipase A2 for early risk stratification in patients with suspected acute coronary syndrome: a multi-marker approach: the North Wuerttemberg and Berlin Infarction Study-II (NOBIS-II).

Authors:  M Möckel; R Müller; J O Vollert; C Müller; O Danne; R Gareis; T Störk; R Dietz; W Koenig
Journal:  Clin Res Cardiol       Date:  2007-06-27       Impact factor: 5.460
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.